Incidence and risk factors for venous thromboembolism in patients with ovarian cancer during neoadjuvant chemotherapy: a meta-analysis

In recent years, there has been increasing recognition of the relationship between neoadjuvant chemo-therapy (NACT) in ovarian cancer and the incidence rate of venous thromboembolism (VTE). Some studies have suggested that NACT may be associated with a high risk of VTE in patients with ovarian cancer. To investigate this, we conducted a systematic review and meta-analysis of the incidence of VTE during NACT and its associated risk factors. We searched PubMed, Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Clinical-Trials.gov, and the International Standard Randomized Controlled Trial Number Register (ISRCTN) from their incep-tion to September 15, 2022. We calculated the incidence of VTE as the event rate (%) and used logistic regression analysis to investigate pooled VTE rates. Risk factors for VTE were presented as odds ratios (ORs), and pooled ORs was estimated using the inverse variance method. We reported pooled effect estimates with 95% confidence inter-vals (CIs). Our review included 7 cohort studies with 1244 participants. Meta-analysis of these studies revealed a pooled VTE rate of 13% during NACT (1224 participants; 95% CI, 9%-17%), with body mass index identified as a risk factor for VTE during NACT in 3 of the included studies (633 participants; OR, 1.76; 95% CI, 1.13-2.76).

Automated summary

In recent years, there has been increased attention to the relationship between neoadjuvant chemotherapy (NACT) in ovarian cancer and the incidence of venous thromboembolism (VTE). This study conducted a systematic review and meta-analysis to investigate the incidence of VTE during NACT and its associated risk factors. The analysis included 7 cohort studies with 1244 participants and found a pooled VTE rate of 13% during NACT, with body mass index identified as a risk factor.